The Good, the Bad, and the Best Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Good, the Bad, and the Best Jobs
Readers provide insight into the best companies to work for as well as the ups and downs of their jobs.

Pharmaceutical Technology
Volume 32, Issue 12, pp. 74-73

Worst aspects of jobs

"Lack of acknowledgment by management of my role."

"Constraints of compliance to change."

"Constant state of not knowing how long we will be employed."

"No rewards for going the extra mile," ... "or for discovery."

"Continuously changing internal requirements."

"High work load as many projects are pushed through the pipeline."

"Turnover" ... "and frequent reorganization."

"Waiting for results from universities."

"A dull and redundant work/repeat" and "shift work."

"No appreciation that we're running a global business and need global processes."

"Regulations, regulations, regulations."

"Lulls in the work cycle."

"Having to contract to people who think they know all the answers."

"Regular panic to meet customer deadlines."

"Management does not listen to or adapt new creative ideas."

"I'm stuck in a deadbeat town somewhere in Germany."

"No improvement in quality of products."

"Working across different time zones."

"Frustrations of failed experiments."

"It's hard to see how my daily activities are advancing the larger strategy."

"Slow computer systems," and "old, unreliable equipment."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here